Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1152.93 +0.49 (0.04%)
Previous Close $1152.44    52 Week High $88.16 
Open $1150.00    52 Week Low $67.88 
Day High $1157.60    P/E 266.88 
Day Low $1140.27    EPS $4.32 
Volume 4,542,506